‘A New Era’: What Next For CRISPR Gene Editing After First Approval?

Analysts, Companies And Researchers Share Their Thoughts On The Field

Emerging out of a landmark 2023, CRISPR companies and researchers are pushing in vivo therapies and other approaches closer to the clinic and potential approval.

An illustration of CRISPR
• Source: Shutterstock

The prospective use of CRISPR-based gene editing has entered a new era with last year’s approval of CRISPR Therapeutics’/Vertex Pharmaceutical’s Casgevy (exagamglogene autotemcel) in key markets, laying down the groundwork for new approaches that use the technology to treat different diseases.

However, perhaps more than ever before, safety remains a key consideration for the space as companies continue pushing different approaches...

More from Innovation

More from In Vivo